Company
IMU Biosciences
We’re decoding the immune system with unprecedented resolution and scale to transform how we understand, diagnose and treat disease.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- London, United Kingdom
- Customers
- clinical research groups, pharma, biotech and diagnostics companies
Claim, correct or request removal
Record updated 28 September 2026
About
IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease
Funding snapshot
- Total raised
- $53MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $53M2026-06-01
Funding rounds
- Series A
- $53M2026-06-01, Company stated
Products
- Other
- HD Immunology platform
- Web
- HD Immunology platform
Loading relationship preview